July 02, 2025

Lean Body Mass–Based Oxaliplatin Dosing and Risk of Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer

In a French phase II trial (LEANOX) reported in the Journal of Clinical Oncology, Assenat et al examined survival outcomes and oxaliplatin-induced peripheral neurotoxicity risk associated with lean bo...

The ASCO Post

July 01, 2025

Our Vision for the Future of Cancer Care

Since 1947, Dana-Farber has been at the forefront of blending exceptional cancer care with leading-edge, transformative science. At the core of what we do is a patient-centered approach with a singular focus — cancer care.

Dana-Farber

July 01, 2025

Metastatic Castration-Resistant Prostate Cancer: Comparison of Second-Line Regimens

As reported in The Lancet Oncology by Agarwal et al, the phase III CONTACT-02 trial examined the survival benefit of cabozantinib plus atezolizumab vs switch of androgen receptor pathway inhibitor (AR...

The ASCO Post

July 01, 2025

HER3-DXd in NSCLC Without EGFR-Activating Mutations

As reported in the Journal of Clinical Oncology by Steuer et al, findings in a cohort of a phase I trial indicated activity of the HER3-directed antibody-drug conjugate patritumab deruxtecan (HER3-DXd...

The ASCO Post

July 01, 2025

Dana-Farber Research News 07.01.2025

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from June 1 through June 15.

Dana-Farber

June 30, 2025

Online Genetic Testing Platform Demonstrates Notable Engagement Among Patients With Young-Onset Colorectal Cancer

In a pilot study being presented at the 2025 ASCO Annual Meeting, Moskowitz et al developed and evaluated an online platform that enables patients with young-onset colorectal cancer to access educatio...

The ASCO Post

June 30, 2025

Invitation to Colonoscopy vs Fecal Immunochemical Test Screening for Colorectal Cancer

Does being invited to colorectal cancer screening with fecal immunochemical tests vs colonoscopy have an impact on colorectal cancer mortality?

The ASCO Post

June 30, 2025

Reduced-Dose Chemoradiotherapy in Early-Stage Anal Cancer

In a UK phase II trial (PLATO-ACT4) reported in The Lancet Oncology, Gilbert et al compared short-term response rates of standard- vs reduced-dose chemoradiotherapy in patients with localized squamous...

The ASCO Post

June 30, 2025

Reduced-Dose Chemoradiotherapy for Early-Stage Anal Cancer

In a UK phase II trial (PLATO-ACT4) reported in The Lancet Oncology, Gilbert et al evaluated whether short-term results showed good complete response rates with both standard-dose and reduced-dose che...

The ASCO Post